EU and National Funds

GINOP_PLUSZ-2.1.1-21-2022-00017

Development of an integrated therapeutic and prevention device to improve tissue oxygenization

Brief description of the project

The main goal is the development of „AngioSmart” telemedicine system, which is an integrated transdermal carbondioxide/tissue nitrogen oxide combined with an intesity-modulated electromagnetic field-based therapy intended to increase tissue oxygen and enhance the repair of damages in microcirculation. The system intended to provide optimised therapy tailored individually, based on the clinical stage and medical conditions for the purpose of rehabilitation or prevention of vulnerable population.

Members of the consortium:

Adware Research Fejlesztési és Tanácsadó Kft.
MEDIX Orvosi Szolgáltató és Tanácsadó Kft.

Grant awarded to Adware Research Kft .: 78 650 000 HUF

Grant intensity: 68.1%

The joint development is expected to end till 31.03.2025.

GINOP-221-18-2020

Intelligent technology-based pediatric post-operative guarding and telemedical home health monitoring system

Brief description of the project

The aim of the project is to develop a complex post-operative surveillance measurement system with a telemedicine option to monitor physical condition at home after surgery. An essential innovation of the measurement interface is that the traditional cardiac surveillance is extended by the monitoring of the gastrointestinal tract.

The realization of the project goal is based on two main groups of development activities 1 / Technical, software and algorithm development 2. / Medical diagnostic development, system testing and human clinical trial.

Members of the consortium:

EN-CO Software Zrt.
Debreceni Egyetem
MSB-MET” Metodikai- Szoftver- Biotechnológiai- Kutató és Fejlesztő
Adware Research Fejlesztési és Tanácsadó Kft.

Grant awarded to Adware Research Kft .: 106 074 322 HUF

Grant intensity: 65.2%

The joint development ends till 31.12.2022.

GINOP-4.1.4-19

Installing solar system at AdWare Research

Brief description of the project

In the frame of the project a 13.2 kWp solar system will be installed at AdWare Research.

Grant awarded: 2 727 435 HUF

Grant intensity: 55 %

The project ends till 07.07.2022.

VÁLLALATI KFI_16

Modular, validated diagnostic measuring and data processing system for human clinical drug development, dietary supplements and medical devices, and for their side effects and other clinical research

Brief description of the project

In recent decades, there has been a real need for research results to be derived from pure traceable data. Recognizing this goal, the members of the consortium (led by PC Trade Kft. – software developer, MDE Kft. – medical device developer, AdWare Research Kft. – data management, biostatistics, data mining service provider) plan to implement a measurement, data management and monitoring system for human clinical research, which meets these requirements and provides an interface to other systems.

The aim of the project is to develop a modular diagnostic tool system that collects data in real time according to the purpose of the study protocol, measures basic physiological parameters (ECG, NIBP, body temperature, CAN, etc.) and is able to receive data from external systems (e.g. laboratory, X-ray, etc.).

Members of the consortium:

PC TRADE Systems Informatikai Kereskedelmi és Szolgáltató Kft.
MDE Orvosbiológiai Kutató, Fejlesztő, Gyártó Kft.
Adware Research Fejlesztési és Tanácsadó Kft.

Grant awarded to Adware Research Kft .: 81 594 858 HUF

Grant intensity: 60 %

The joint development ends till 30.06.2019.

GINOP-2.1.7-15

Development of a non-invasive complex measurement and evaluation system for the diagnosis of childhood reflux disease

Brief description of the project

The aim of the project is to develop a prototype of a complex measurement tool and an organically related diagnostic evaluation module that would allow the non-invasive diagnosis of childhood gastroesophageal reflux disease (GERD) under ambulatory conditions by replacing the currently used invasive measurement techniques.

Grant awarded: 64 932 000 HUF

Grant intensity: 60 %

The development ends till 30.06.2019.

GINOP-2.2.1-15

Development of a new, multi-point innovative analgesic: efficacy, preclinical and human phase I studies

Brief description of the project

The aim of the development is to prove the efficacy and safety of the drug candidate SZV-1287 by preclinical studies and to launch human clinical trials in accordance with international requirements. The main stages of the project are: I.) completion of preclinical studies: complete characterization of the analgesic effect profile, drug formulation, pharmacokinetic and subacute toxicological studies, as well as the necessary synthetic chemical and analytical work, production of active substance; compilation of preclinical documentation according to official requirements; II.) To perform the Phase I clinical trial.

Members of the consortium:

Toxi-Coop Toxikológiai Kutatóközpont Zrt.
Pécsi Tudományegyetem
Adware Research Fejlesztési és Tanácsadó Kft.

Grant awarded to Adware Research Kft .: 61 600 000 HUF

Grant intensity: 78,77 %

The joint development ends till 30.11.2022

FP7 – PATHWAY-27

Pivotal assessment of the effects of bioactives on health and wellbeing. From human genoma to food industry.

Brief description of the project

PATHWAY-27, a pan-European interdisciplinary team of life/social scientists and high tech/ food processing SMEs, uniquely addresses the role and mechanisms of action of 3 bioactives, namely docosahexaenoic acid (DHA), β-glucan (BG),and anthocyanins (AC), fortifying 3 different widely-consumed food matrices (dairy-, bakery-, egg products).

Critical evaluation of bioactive-food matrix interactions and determining the extent of synergies between the 3 bioactives are key elements of PATHWAY-27. The project will also consider the technological modifications occurring during food processing and production, as well as the frequency of consumption and the consumers’ acceptance of the BEF.

Countries taking part int he project: